ChartRow logo
Data provided bySource: Twelve Data
ARWR
$42.99-2.76%
as of close, Nov 17, 2026
☾ AH $42.99 -2.76%
PeersROIVAXSMCYTKIBRXSPYQQQ
Share this page

ARWR financial statements

The full income statement, balance sheet, and cash-flow statement for Arrowhead Pharmaceuticals Inc. (ARWR), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +26.7%10Y CAGR +121.5%YoY −85.3%
$450.8M FY26$37.8M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$707.2M FY26−$436.6M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Net income

5Y n/m10Y n/mYoY n/m
−$724.2M FY26−$428M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$5.11 FY26−$3.00 Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Operating cash flow

5Y n/m10Y n/mYoY n/m
−$271.9M FY26−$192.4M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Capital expenditure

5Y CAGR −12.6%10Y CAGR +12.0%YoY −54.2%
$12M FY26$3.4M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$283.9M FY26−$195.8M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Shares (diluted)

5Y +36.5%5Y +36.5%YoY +5.6%
141.6M FY26142.5M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Every ARWR chart on Trends →

Shares outstanding (point-in-time)

2024-09 124.4M2024-12 126.1M2025-03 138.1M2025-06 138.3M2025-09 135.8M2025-12 140.0M2026-03 140.9M2026-06 141.3M2026-09 141.4M+13.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2026FY2025FY2024FY2023FY2022
Income Statementas ofSep 30 ’26as ofSep 30 ’25as ofSep 30 ’24as ofSep 30 ’23as ofSep 30 ’22
Revenue451M-45.6%829M+23258.2%3.55M-98.5%241M-1.0%243M+75.9%
1.16B+58.4%731M+20.9%605M+35.6%446M+5.7%422M+46.8%
Research & development739M+21.7%607M+20.0%506M+43.2%353M+18.8%297M+44.1%
Selling, general & administrative202M+63.0%124M+25.5%98.8M+6.7%92.5M-25.6%124M+53.7%
General & administrative—124M+25.5%98.8M+6.7%92.5M-25.6%124M+53.7%
Amortization of intangibles1.70M+0.0%1.70M+0.0%1.70M+0.0%1.70M+0.0%1.70M+0.0%
Operating income-707M-819.1%98.3M+116.4%-601M-193.2%-205M-14.8%-179M-19.8%
Interest expense93.7M+4.9%89.4M+176.2%32.4M+76.5%18.3M0.00
Other non-operating income3.98M-24.3%5.26M+400.9%-1.75M-213.7%1.54M+101.0%765K-63.0%
Equity-method income-11.5M0.000.00——
Pre-tax income-724M-1504.8%51.5M+108.4%-612M-196.6%-206M-19.6%-173M-22.6%
Income tax-6.78M-131.7%21.4M+874.1%-2.77M-199.4%2.78M-26.4%3.79M+189150.0%
-724M-44302.6%-1.63M+99.7%-599M-192.0%-205M-16.6%-176M-25.0%
Net income to non-controlling interest7.07M-77.7%31.7M+411.2%-10.2M-155.0%-4.00M-828.1%-431K
Net income to common-724M-44302.6%-1.63M+99.7%-599M-192.0%-205M-16.6%-176M-25.0%
-$5.11-51000.0%-$0.01+99.8%-$5.00-160.4%-$1.92-15.0%-$1.67-22.8%
EPS (basic)-$5.11-51000.0%-$0.01+99.8%-$5.00-160.4%-$1.92-15.0%-$1.67-22.8%
Weighted-avg shares (basic)142M+5.9%134M+11.7%120M+12.2%107M+1.3%105M+1.6%
Weighted-avg shares (diluted)142M+5.9%134M+11.7%120M+12.2%107M+1.3%105M+1.6%
Balance Sheetas ofSep 30 ’26as ofSep 30 ’25as ofSep 30 ’24as ofSep 30 ’23as ofSep 30 ’22
1.29B+35.6%951M+36.7%695M+67.0%416M+2.8%405M+5.4%
Cash & equivalents62.7M-72.3%227M+120.6%103M-7.4%111M+2.7%108M-41.4%
Short-term investments—693M——0.00-100.0%
Accounts receivable9.93M+45.6%6.82M0.000.00-100.0%1.41M-86.3%
Inventory9.07M0.00———
Prepaid expenses31.6M+188.8%10.9M+14.6%9.54M+8.2%8.81M+20.9%7.29M+67.1%
Other current assets45.7M+237.8%13.5M+171.8%4.97M+23.3%4.03M-80.0%20.2M+822.1%
1.74B+25.5%1.39B+21.5%1.14B+48.9%766M+10.6%692M-2.6%
Property, plant & equipment371M-2.9%383M-0.9%386M+33.0%290M+163.2%110M+126.6%
Operating lease right-of-use58.3M+32.9%43.9M-3.0%45.3M-0.1%45.3M-22.3%58.3M+236.0%
Intangible assets5.16M-24.8%6.86M-19.9%8.56M-16.6%10.3M-14.2%12.0M-12.4%
Other non-current assets14.2M+924.2%1.39M-69.0%4.48M+37.5%3.26M+1395.0%218K-19.9%
311M+59.3%195M+89.5%103M-2.2%105M-24.1%139M-5.2%
Accounts payable30.1M+70.6%17.7M+55.2%11.4M-68.2%35.9M+1150.6%2.87M-69.7%
Accrued liabilities104M+15.0%90.4M+43.5%63.0M+58.5%39.8M-15.1%46.9M+234.7%
Deferred revenue91.6M+3720.3%2.40M0.00-100.0%866K-98.8%74.1M-33.3%
Short-term & current debt40.0M+0.0%40.0M0.00——
Current lease liability5.50M-24.6%7.29M+14.9%6.34M-40.0%10.6M+280.5%2.78M+23.4%
Other current liabilities7.01M-35.2%10.8M+2402.5%432K-0.7%435K0.00
1.69B+91.4%882M-7.0%949M+98.3%478M+74.9%274M-9.2%
Long-term debt839M+290.4%215M-45.3%393M0.00—
Deferred revenue (non-current)21.3M0.00—0.00-100.0%56.0M-57.5%
Non-current lease liability116M+11.2%104M-6.2%111M+6.1%105M+32.8%78.8M+238.3%
Operating lease liability (total)121M+8.9%111M-5.1%117M+1.9%115M+41.2%81.6M+219.3%
Other non-current liabilities
————0.00
Total non-current liabilities1.38B+100.5%686M-18.8%846M+126.7%373M+176.8%135M-12.9%
50.3M-89.2%466M+151.3%185M-31.7%271M-31.9%399M-2.5%
Common stock237K+2.6%231K+6.5%217K+8.5%200K+1.0%198K+0.5%
Additional paid-in capital2.46B+15.1%2.14B+18.5%1.81B+38.9%1.30B+6.7%1.22B+15.7%
Retained earnings-2.35B-44.5%-1.63B-0.1%-1.63B-58.4%-1.03B-25.0%-821M-27.3%
Treasury stock53.2M+0.0%53.2M0.00——
Accumulated other comprehensive income-7.65M-218.7%6.44M+35.6%4.75M+247.4%-3.22M-2269.1%-136K-97.1%
Non-controlling interest191K-99.5%37.4M+565.0%5.62M-64.5%15.8M-20.2%19.8M
Total equity incl. non-controlling50.5M-90.0%503M+163.5%191M-33.5%287M-31.4%418M+2.3%
Total liabilities & equity1.74B+25.5%1.39B+21.5%1.14B+48.9%766M+10.6%692M-2.6%
Common shares issued144M+4.0%138M+11.2%124M+15.9%107M+1.3%106M+1.6%
Common shares outstanding141M+4.1%136M+9.1%124M+15.9%107M+1.3%106M+1.6%
Shares outstanding (cover)141M+4.1%136M+9.1%124M+15.8%107M+1.3%106M+1.4%
Treasury shares2.66M+0.0%2.66M———
Cash Flowas ofSep 30 ’26as ofSep 30 ’25as ofSep 30 ’24as ofSep 30 ’23as ofSep 30 ’22
-272M-251.5%180M+138.8%-463M-200.8%-154M-13.0%-136M-179.5%
Depreciation & amortization26.6M+11.3%23.9M+28.7%18.6M+48.8%12.5M+19.9%10.4M+26.1%
Intangible amortization1.70M+0.0%1.70M+0.0%1.70M+0.0%1.70M+0.0%1.70M+0.0%
Share-based compensation68.1M+7.5%63.4M-14.3%74.0M-5.3%78.1M-35.4%121M+57.7%
Deferred income taxes0.000.000.000.000.00
Change in receivables3.29M-94.2%57.0M0.00+100.0%-1.41M+84.1%-8.85M-194.0%
Change in inventory9.07M0.000.00——
Change in payables12.5M+98.5%6.29M+213.5%-5.54M-116.8%33.0M+600.8%-6.59M-350.7%
-670M-418.6%-129M+69.2%-420M-336.9%-96.2M-1675.1%-5.42M+96.2%
Capital expenditure12.0M-47.1%22.7M-84.0%141M-20.0%177M+234.9%52.8M+123.9%
Free cash flow-284M-281.0%157M+126.0%-604M-82.8%-331M-75.0%-189M-227.9%
Acquisitions0.000.000.000.000.00
Purchases of investments—796M+10.4%721M+192.9%246M+10.2%223M-7.2%
Sales/maturities of investments368M-46.6%690M+55.9%442M+35.4%327M+20.7%271M+120.9%
777M+949.7%74.0M-91.5%871M+244.0%253M+288.2%65.2M+476.6%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued—241M-43.8%429M0.000.00
Common stock repurchased0.00—0.000.000.00
Dividends paid0.000.000.000.000.00
FX effect on cash—-401K-109.6%4.20M+3540.2%-122K-82.1%-67.0K+23.9%
Interest paid0.00-100.0%19.0K0.000.000.00
Income taxes paid21.6M+2751.6%-814K-121.7%3.74M0.00+100.0%-2.00K+0.0%
Valuation Ratiosas ofSep 30 ’26as ofSep 30 ’25as ofSep 30 ’24as ofSep 30 ’23as ofSep 30 ’22
Market cap9.25B+97.6%4.68B+94.3%2.41B-16.4%2.88B-17.8%3.50B-46.2%
P/S20.5×+263.5%5.6×-99.2%678.4×+5935.1%11.2×-21.9%14.4×-69.4%
P/B183.8×+1730.2%10.0×-22.7%13.0×+64.6%7.9×-10.2%8.8×-44.8%
P/FCF
—29.8×———
FCF yield
—3.4%———
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Christopher Anzalone$9M$42.6M$2.1M$80.00$146.00
FY2024—$12.4M−$5.4M$3.5M$31.00$94.00
FY2023—$9.9M−$2.2M$3.2M$62.00$49.00
FY2022—$12M−$40.1M$4.1M$77.00$67.00
FY2021—$24.7M$69.1M$3.3M$145.00$116.00

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: ARWR’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ARWR filings on SEC EDGAR → Not investment advice.